Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials
Endocrinology, Diabetes & Metabolism · 2026-05 · 9 (3)
DOI: 10.1002/edm2.70218 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Endocrinology, Diabetes & Metabolism, online erschienen am 07.04.2026. Verfasst von Doha Jaber und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Al-Quds University, Jerusalem, Palestine. Hauptthemen laut MEDLINE: Fatty Liver, Fibroblast Growth Factors, Metabolic Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aim Metabolic dysfunction‐associated steatohepatitis (MASH) is a progressive liver condition and a major cause of cirrhosis, hepatocellular carcinoma, and liver transplantation. Resmetirom, a thyroid hormone receptor β agonist, and Efruxifermin, a fibroblast growth factor 21 analogue, have shown promise in improving hepatic fat fraction (HFF) and liver enzyme levels. This study systematically compares the efficacy and safety of Resmetirom and Efruxifermin in treating MASH.
Methods
A systematic search of PubMed, Cochrane, and Scopus identified 211 studies, of which eight randomized controlled trials (RCTs) were included. Primary outcomes included reductions in liver enzyme levels. Secondary outcomes assessed HFF measured by magnetic resonance imaging‐derived proton density fat fraction (MRI‐PDFF), as well as lipid profiles. Safety outcomes consist of serious adverse events and events leading to treatment discontinuation.
Results
Efruxifermin was associated with significant improvement in MRI‐PDFF with an mean difference (MD) of −62.83% (95% CI: −72.30 to −53.36, p = 0.00), followed by Resmetirom with an MD of −37.15% (95% CI: −44.43 to −29.88, p = 0.00), additionally Efruxifermin was associated with significant reduction in aspartate transferase (AST) level, with an MD of −14.32 (95% CI: −23.92 to −4.72, p = 0.003), compared to Resmetirom (MD: −2.81; 95% CI: −12.40 to 6.79, p = 0.56). For lipid profiles, Efruxifermin showed a significant reduction in triglyceride levels with an MD of −36.95 (95% CI: −52.67 to −21.24, p = 0), while Resmetirom had an MD of −24.72 (95% CI: −33.31 to −16.14, p = 0.00).
Conclusion
Efruxifermin demonstrated a slightly greater effect on MRI‐PDFF and AST, along with more favourable safety outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Al-Quds University, Jerusalem, Palestine.
- Department of Internal Medicine, Unity Hospital, Rochester Regional Health, Rochester, New York, USA.
- Deaconess Health System, Evansville, Indiana, USA.
ORCID-Profile: Doha Jaber, Ayah Abu Lehia, Hazem Ayesh
Zitieren
APA
Jaber, D., Jaber, I., Lehia, A. A., Asad, T., & Ayesh, H. (2026). Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism, 9(3). https://doi.org/10.1002/edm2.70218
Vancouver
Jaber D, Jaber I, Lehia AA, Asad T, Ayesh H. Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials. Endocrinology, Diabetes & Metabolism. 2026;9(3). doi:10.1002/edm2.70218
BibTeX
@article{Jaber2026,
author = {Jaber, Doha and Jaber, Inas and Lehia, Ayah Abu and Asad, Thekrayat and Ayesh, Hazem},
title = {Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials},
journal = {Endocrinology, Diabetes & Metabolism},
year = {2026},
volume = {9},
number = {3},
doi = {10.1002/edm2.70218}
}
EUVIMED